Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2001

View Archived Issues

Licensing opportunity from NIH: BRCA1 mutants for modulating cellular response to DNA damage

Licensing opportunity from NIH: specific binding agents for KSHV vIL-6

Promising data reported for Visudyne in occult AMD and pathological myopia

IL-1ra protects cortical neurons following transient middle cerebral artery occlusion

Inhale Therapeutic Systems makes significant progress during 2000

American Biogenetic Sciences highlights 2000 progress, provides outlook for 2001

Independent cardiovascular study with Dusa's Levulan begins

Adjunctive treatment with Cerebrolysin associated with neuroprotection in acute ischemic stroke

Effects of BMP-7 in rats with transient MCA occlusion discussed at this week's stroke conference

Inflazyme reports company update

Potent PPAR agonists and their use presented by Merck & Co.

AstraZeneca dedicates resources to discovery of safe neuroprotective compounds

Novel imidazolines only stimulate insulin release during hyperglycemia

Thrombin inhibitors with high selectivity designed at ADIR

Mochida describes new series with potent cholesterol-lowering effects

Pierre Fabre reports imidazolines structurally related to idazoxan and potential uses

Patent issued to Welfide covers new IL-4/IL-5 production inhibitors

Discovery of prostate cancer gene detailed by Myriad

Involvement of MAPK, therapeutic role for MAPK inhibitors in cerebral vasospasm

Draxis Health cleared to begin phase II trials with AMI diagnostic in U.S. and Canada

Genta's Genasense enters phase III evaluation for multiple myeloma

Significant neuroprotective effects demonstrated for kappa opioid agonist

Theratechnologies commences phase II trials in sleep disorders

Dyax and Debiopharm move cystic fibrosis treatment into phase II

Beneficial effects of long-term glucosamine sulfate on osteoarthritis progression

Ilex Oncology acquires Symphar; Symphar becomes Ilex Research-Europe

Potential new agent for reducing NIDDM-associated hyperglycemia without side effects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...